Increased Uptake of BRCA1/2 Genetic Testing Among African American Women with a Recent Diagnosis of Breast Cancer
Overview
Authors
Affiliations
Purpose: Studies suggest that African American women are less likely to pursue BRCA1/2 genetic testing than white women. However, such studies are often confounded by unequal access to care.
Methods: Data from 132 African American and 636 white women, obtained from a clinical database at the University of North Carolina (Chapel Hill, NC) between 1998 and 2005, were analyzed to assess BRCA1/2 genetic testing uptake. Importantly, the clinical setting minimized barriers of both cost and access. Race and time of new breast cancer diagnosis (recent v > 1 year before genetic evaluation) were assessed for association with BRCA1/2 testing uptake using multivariable logistic regression models.
Results: Both race (P = .0082) and a recent diagnosis of breast cancer (P = .014) were independently associated with testing uptake. African American women had a lower estimated odds of pursuing testing than white women (odds ratio [OR], 0.54; 95%CI, 0.34 to 0.85), and women with a recent diagnosis had a higher OR than those with a remote diagnosis (OR, 1.58; 95% CI, 1.10 to 2.29). In a race-stratified analysis, there was no statistical evidence for association between recent status and testing uptake in the larger white stratum (OR, 1.38, P = .13) while there was for the smaller African American sample (OR, 2.77, P = .018). The test of interaction between race and remote status was not significant (P = .15).
Conclusion: African American race was associated with an overall decreased uptake of BRCA1/2 genetic testing, even when barriers of ascertainment and cost were minimized. However, among African American women, a recent diagnosis of breast cancer was associated with substantially increased uptake of testing.
Disparities in Genetic Testing for Inborn Errors of Immunity.
Gilbert K, McLaughlin H, Farmer J, Ong M J Allergy Clin Immunol Pract. 2024; 13(2):388-395.e3.
PMID: 39579980 PMC: 11807750. DOI: 10.1016/j.jaip.2024.11.011.
Iwai Y, Toumbou K, Zuze T, Morgan J, Simwinga L, Wright S JCO Glob Oncol. 2023; 9:e2300154.
PMID: 37944088 PMC: 10645409. DOI: 10.1200/GO.23.00154.
Choi J, Fikre T, Fischman A, Buck A, Ko N Oncologist. 2022; 27(10):832-838.
PMID: 36124631 PMC: 9526492. DOI: 10.1093/oncolo/oyac132.
Henderson V, Madrigal J, Kendall L, Parekh P, Newsome J, Chukwudozie I BMC Health Serv Res. 2022; 22(1):826.
PMID: 35752812 PMC: 9233847. DOI: 10.1186/s12913-022-08193-x.
Healthcare Predictors of Information Dissemination About Genetic Risks.
Henderson V, Strayhorn S, Bergeron N, Strahan D, Ganschow P, Khanna A Cancer Control. 2022; 29:10732748221104666.
PMID: 35658635 PMC: 9174561. DOI: 10.1177/10732748221104666.